BioIVT published results from a new publication featuring researchers using the HEPATOPAC long-term hepatic MPS micropatterned co-culture system.
Public source
Publisher name
Public post
Another publication added to the long list of researchers publishing their results using the #HEPATOPAC long-term hepatic MPS! With more and more drug developers integra…
Company
BioIVT
ELEVATING SCIENCE
- Industry
- Biotechnology Research
- Location
- Woodbury, US
- Company size
- 201–500 employees
About BioIVT
BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease state samples including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our Research Services team works collaboratively with clients to provide in vitro hepatic modeling solutions. And as the world’s premier supplier of ADME-Tox model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®.
See moreLatest activity
Latest activity from BioIVT
19 signals
Products & Services
BioIVT launched a new Voluntary Data Submission pilot allowing companies, method developers, CROs, academic laboratories, consortia, and other stakeholders to submit and discuss NAM data independently of a Marketing Authorisation Application.
Research & Knowledge
BioIVT published results from a new publication featuring researchers using the HEPATOPAC long-term hepatic MPS micropatterned co-culture system.
Research & Knowledge
BioIVT learned about the EMA's new Voluntary Data Submission program, which will provide participants with individual, non-binding, and non-decisional feedback on the regulatory relevance and readiness of their NAM or weight-of-evidence approach.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
CN Bio
CN Bio published a newly published paper providing insight into how collaborative cross-platform evaluation studies for liver MPS can be designed and implemented.
Research & Knowledge
MatTek Life Sciences
MatTek Life Sciences published an article in Microtissue Matters by Alex Armento discussing NAMs adoption and its impact on R&D.
Research & Knowledge
Celvivo
Celvivo published a study in Cell Reports by Cell Press published in 2026 detailing the development of rotational 3D trophoblast organoids in Tohoku University School of Medicine, ROHTO Pharmaceutical Co., Ltd., and the Institute of Molecular Embryology and Genetics at Kumamoto University.
Research & Knowledge
PhoenixBio
PhoenixBio published a study pairing InnoCell oxygen-permeable plates with PXB-cells, a unique source of primary human hepatocytes that support long-term testing.
Research & Knowledge
IVTech